Contact CFFC

Sep

Clinical Trial Alerts – September 2017

Cystic Fibrosis Foundation distributed the following clinical trial updates during the month of September. Click the trial title to get more details.

CFF issued the following alert on 09/01/2017.

Phase 2 study of LAU-7b in adults with CF (APPLAUD)

Status: Enrolling

Description: This study is taking place at multiple care centers across the U.S. It will look at the safety and effectiveness of the anti-inflammatory drug LAU-7b and will use a placebo control.

Age: 12 Years and Older

Mutation: No Mutation Requirement

Fev1% Predicted: 50 to 90%

Number of Visits: 6

Length of Participation: 189 days

ClinicalTrials.gov link: https://clinicaltrials.gov/ct2/show/NCT03265288

CFF issued the following alert on 09/14/2017.

Phase 3 study of inhaled vancomycin in adults and children 6 years and older with cystic fibrosis

Status: Enrolling

Description: This study is taking place at multiple care centers across the U.S. It will look at the effectiveness of the inhaled drug vancomycin in adults and children 6 years and older with cystic fibrosis and positive cultures for methicillin-resistant Staphylococcus aureus (MRSA).

Age: 6 Years and Older

Mutation: No Mutation Requirement

Fev1% Predicted: 30 to 100%

Number of Visits: 8

Length of Participation: 12 months

ClinicalTrials.gov link: https://www.clinicaltrials.gov/ct2/show/NCT03181932?term=NCT03181932

CFF issued the following alert on 09/19/2017.

Phase 3 study of long-term ivacaftor in babies who have a CFTR gating mutation

Status: Enrolling

Description: This open-label study is taking place at multiple care centers across the U.S. It will look at the safety and effectiveness of long-term ivacaftor in babies who have a CFTR gating mutation.

Age: 0 Days to 24 Months

Mutation: One Copy F508del or No Copies F508del

Fev1% Predicted: No FEV1 Limit

Number of Visits: 18

Length of Participation: 128 weeks

ClinicalTrials.gov link: https://clinicaltrials.gov/ct2/show/NCT03277196


Comments are closed.